Compare YQ & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YQ | ACET |
|---|---|---|
| Founded | 2012 | 1947 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.8M | 28.0M |
| IPO Year | 2020 | 2017 |
| Metric | YQ | ACET |
|---|---|---|
| Price | $2.55 | $2.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $29.00 |
| AVG Volume (30 Days) | 3.1K | ★ 284.0K |
| Earning Date | 12-08-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $274.52 | N/A |
| Revenue Next Year | $29.79 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.68 | $0.46 |
| 52 Week High | $5.25 | $9.97 |
| Indicator | YQ | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 37.29 | 15.61 |
| Support Level | $2.44 | N/A |
| Resistance Level | $2.63 | $9.51 |
| Average True Range (ATR) | 0.23 | 0.26 |
| MACD | -0.01 | 0.08 |
| Stochastic Oscillator | 2.94 | 4.69 |
17 Education & Technology Group Inc is engaged in providing education and education technology services in the People's Republic of China (PRC) with a focus on the Teaching and Learning SaaS offerings. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).